Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.6000
-0.0585 (-8.88%)
May 15, 2026, 4:00 PM EDT - Market closed
Galmed Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Galmed Pharmaceuticals stock has a target of 12, which predicts a 1,900.00% increase from the current stock price of 0.6.
Price Target: $12 (+1,900.00%)
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Galmed Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 4, 2025 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $48 | Hold → Strong Buy | Upgrades | $48 | +7,900.00% | Jul 24, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 8, 2022 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $900 → $180 | Strong Buy → Hold | Downgrades | $900 → $180 | +29,900.00% | Aug 8, 2022 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 18, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.59
from -2.39
EPS Next Year
-0.92
from -1.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.64 | -0.95 | |
| Avg | -1.59 | -0.92 | |
| Low | -1.53 | -0.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.